- Details
- Thomas Hope, MD highlights how he came to study somatostatin receptor-based molecular Imaging for neuroendocrine tumors (NET). He takes us back to 2013, to the World Theranostics Conference at Hopkins, focused on neuroendocrine tumors because at that time there were no prostate theranostics. For this work, they put together a gallium dotatate program, which required the same synthesis module requi...
|
- Details
- 68 Ga-PSMA-11, the first drug for PET imaging of prostate-specific membrane antigen (PSMA)–positive lesions in men with prostate cancer (PC), was approved on December 1, 2020, by the United States Federal Drug Administration (FDA). Joining Phillip Koo is Johannes Czernin, one of the original pioneers who started the process of getting gallium-68 PSMA approved in the United States. Dr. Czernin deta...
|
- Details
- In this special patient-centered educational video from the Society of Nuclear Medicine and Molecular Imaging (SNMMI), Robert Flavell, an Assistant Professor and the Chief of Molecular Imaging and Therapeutics at the University of California in San Francisco presents on PSMA PET imaging. Dr. Flavell's lecture focuses on how PSMA PET is used in diagnosing prostate cancer and presents a case study o...
|
- Details
- On December 1, 2020, the US Food and Drug Administration approved Gallium 68 PSMA-11 (Ga 68 PSMA-11) for use for patients with suspected prostate cancer metastasis in UCLA and UCSF. It is the first drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. In a follow-up conversation after speaking about the approv...
|
- Details
- Jeremie Calais, MD, MSc, joins Phillip Koo, MD, FACS, to discuss the approval of Gallium 68 PSMA-11, the first agent for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. The safety and efficacy of Ga 68 PSMA-11 were evaluated in two prospective clinical trials, which lead to the United States Federal Drug Administ...
|
- Details
- 68 Ga-PSMA-11, the first drug for PET imaging of prostate-specific membrane antigen (PSMA)–positive lesions in men with prostate cancer (PC), was FDA approved on December 1, 2020. The approval was granted to the University of California–San Francisco (UCSF) and UC–Los Angeles (UCLA). 68 Ga-PSMA-11 is indicated for suspected metastatic disease at the time of initial staging prior to definitive ther...
|
- Details
- Stefano Fanti joins Phillip Koo in conversation on establishing the PSMA PET/CT, as the gold standard with regards to imaging for prostate cancer, expectations, accuracy when it comes to imaging, how that CT should be performed, and limitations with regards to trial design for diagnostic imaging agents. Dr. Fanti offers advice for nuclear medicine physicians and radiologists in the community with...
|
- Details
- Michael Morris, Oliver Sartor, and Alicia Morgans discuss the CONDOR study, the second of two prospective clinical trials designed in collaboration with the FDA to demonstrate the diagnostic performance of PyL in patients with biochemically recurrent prostate cancer. Correct localization rate (CLR), or the positive predictive value of the PyL scan, was established as the primary endpoint and the C...
|
- Details
- In conversation with Charles Ryan, Thomas Hope details the prospective, multicenter single-arm open-label phase 3 imaging trial evaluating the accuracy of 68Ga-PSMA-11 for pelvic nodal metastasis detection prior to radical prostatectomy or definitive treatment and pelvic lymph node dissection. Between UCLA and UCSF 277 patients went through prospective imaging. When comparing these patients to nod...
|
- Details
- Declan Murphy and Michael Hofman join Alicia Morgans to discuss the results from proPSMA study "A prospective randomized multi-center study of the impact of Ga-68 PSMA-PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy." Conventional imaging using CT and bone scan has insufficient sensitivity when staging men with high-risk localized prostate canc...
|
